Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis

Ведущий спонсор: Immunic AG

Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis - CALLIPER

This study will be a multicenter, randomized, double-blind, placebo-controlled study with a blinded Main Treatment Period (MT) and an Open Label Period (OLE) to evaluate the efficacy, safety, and tolerability of IMU838 in adult patients with PMS. The study will consist of the following periods: Screening Period: Approximately 28 days Main Treatment Period: Up to 120 weeks (approximately 2 years) Open Label Extension Period: Up to approximately 8 years

• Multiple Sclerosis

Тип вмешательства: Drug

Название вмешательства: IMU-838

Описание: IMU-838 tablets

Этикетка Arm Group: IMU-838

Другое имя: Vidofludimus calcium

Тип вмешательства: Drug

Название вмешательства: Placebo matching IMU-838

Описание: Placebo matching IMU-838 tablets

Этикетка Arm Group: Placebo

Другое имя: Placebo Arm

Критерии:

Inclusion Criteria: - Adult patients, age 18 to 65 years (inclusive). - EDSS score at screening between 3.0 to 6.5 (both inclusive) - No evidence of relapse in the last 24 months before randomization, AND Patients diagnosed according to 2017 revised McDonald Criteria 1 and the 2013 revised classification of disease courses 2 as either 1. SPMS inpatients showing evidence of Gd+MRI lesions (active SPMS) or without Gd+MRI lesions (non-active SPMS) in the last 12 months, OR 2. PPMS - Willingness and ability to comply with the protocol. - Written informed consent given by the patient before the beginning of any study-related procedure. - Documented evidence of disability progression not temporarily related to a relapse in the last 24 months before randomization, adjudicated by a central independent reviewer Exclusion Criteria: - Any disease other than MS that may better explain the signs and symptoms, including a history of complete transverse myelitis. - Clinical signs or presence of laboratory findings suggestive for neuromyelitis optica (NMO) spectrum disorders or myelin oligodendrocyte glycoprotein (MOG)-associated encephalomyelitis (i.e.,presence of anti-NMO [aquaporin-4] antibodies or anti-MOG antibodies). - Previous or current use of MS treatments lifelong, or within a pre-specified time period. - Use of any investigational product within 8 weeks or 5 the respective PK half- life before the date of informed consent, whichever is longer, and throughout the study.For some investigational products, prolonged biological effects beyond 8 weeks should be considered. - Positive test for severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) within14 days before randomization. In case of known SARS-CoV-2 infection, patients should be randomized no earlier than 14 days after 2 consecutive negative tests confirming virus negative status.The screening period can be extended for these patients to accommodate the required virus negativity. - Positive IFN-gamma release assay (IGRA) for Mycobacterium tuberculosis at SV1. - Positive hepatitis B virus (HBV) surface antigen, hepatitis B core antibody, positive hepatitis C virus (HCV) antibody, and/or HIV-antigen-antibody test at SV1.

Пол:

All

Минимальный возраст:

18 Years

Максимальный возраст:

65 Years

Здоровые волонтеры:

No

Фамилия: Andreas Muehler, MD

Телефон: +49 89 2080 477 00

Bulgaria

Poland

Ukraine

United States

2022-01-01

Тип: Sponsor

• Progressive Multiple Sclerosis

• Multiple Sclerosis
• Multiple Sclerosis, Chronic Progressive
• Sclerosis

Метка: IMU-838

Тип: Experimental

Описание: IMU-838 as tablet; Administration: Oral - daily

Метка: Placebo

Тип: Placebo Comparator

Описание: Matching placebo as tablet; Administration: Oral - daily

Распределение: Randomized

Модель вмешательства: Parallel Assignment

Первичное назначение: Treatment

Маскировка: Double (Participant, Investigator)